Innovative Medicines Initiative (IMI) 4th Call 2011

Based on the recommendations of the IMI Research Agenda, the IMI Governing Board has approved the IMI Annual Implementation Plan 2011, including the Scientific Priorities 2011. These priorities have been incorporated into the IMI 4th Call Topics. These priorities have been incorporated into the IMI 4th Call Topics. Applicants intending to submit an Expression of Interest (EoI) in response to the IMI 4th Call should read the Guide for Applicants, the Call Topics, the Rules for Participation, the Rules for Submission, Evaluation and Selection of EoIs and FPPs, the IMI IPR rules and the IMI JU model Grant Agreement.

Call Identifier: IMI-JU-2011

Call status: Open for Submission of Expression of Interest from 19 September 2011.

Budget: A maximum financial contribution from the European Community to the IMI JU for the support of research activities of € 105 million, matched by the in-kind contribution by the research based companies that are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Call documents: The key documents required for the preparation of your Expression of Interest (EoI):

  • Call 4 topics text (IMI-GB-DEC-2011-09.1)
  • Guide for Applicants Expressions of Interest (IMI-GB-DEC-201109.4)
  • Rules for Participation (IMI-GB-DEC-2011-09.5)
  • Rules for Submission, Evaluation and Selection of Expressions of Interest and Full Project Proposals (IMI-GB-DEC-2011-09.2)
  • IMI 4th Call Evaluation Form - Stage 1 (IMI-GB-DEC-2011-09.3)
  • IP Policy
  • Model Grant Agreement

Submissions start date (for submitting EoIs): 19 September 2011

Submissions deadline (for submitting EoIs): 18 October 2011

For further information and the key documents, please visit:

About IMI
The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients.

With a €2 billion euro budget, IMI supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. Acting as a neutral third party in creating innovative partnerships, IMI aims to build a more collaborative ecosystem for pharmaceutical research and development (R&D). IMI will provide socio-economic benefits to European citizens, increase Europe's competitiveness globally and establish Europe as the most attractive place for pharmaceutical R&D.